Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. by Rankin, N, Preiss, D, Welsh, P, Sattar, N

Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: Meta-analysis of 119 clinical trials involving 100,667 patients by Willeit, P, Tschiderer, L, Allara, E, Preiss, D

Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe by Achelrod, D, Gray, A, Preiss, D, Mihaylova, B

PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study by Preiss, D, Holmes, M, Fairhurst-Hunter, Z, Mahajan, A

Associations of targeted circulating microRNAs with insulin resistance in the CAMERA (Carotid Atherosclerosis: MEtformin for insulin ResistAnce) trial by Alramah, T, Preiss, D, Sattar, N, Logue, J, Welsh, P

The role of emerging risk factors in cardiovascular outcome by Lacey, B, Herrington, W, Preiss, D, Lewington, S, Armitage, J

Universal singular sets in the calculus of variations by Csornyei, M, Kirchheim, B, O'Neil, T, Preiss, D, Winter, S

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials by Preiss, D, Armitage, J, Holman, R, Coleman, R, Spata, E

Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland by Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B

Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes by Welsh, P, Preiss, D, Hayward, C, Woodward, M, al, E

Metabolic profiling of MRI-measured liver fat in the UK Biobank by Gnatiuc Friedrichs, L, Trichia, E, Aguilar-Ramirez, D, Preiss, D

GDF15 mediates the effects of metformin on body weight and energy balance by Coll, A, Chen, M, Taskar, P, Preiss, D, et al.

Towards an understanding of the ethics of electronic consent in clinical trials by Sahan, K, Wijesurendra, R, Preiss, D, Mafham, M, Sheehan, M

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017 by Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B

Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease by Schwartz, GG, Leiter, LA, Ballantyne, CM, Preiss, D, Et al.

Putative miRNA biomarkers of insulin resistance and the effect of metformin: data from the CAMERA trial by ALRamah, T, Pinel, K, Preiss, D, Sattar, N, Logue, J, Welsh, P

Diabetic retinopathy and quality of life: a systematic review and Meta-analysis by Zayed, M, Karsan, W, Peto, T, Saravanan, P, Virgili, G, Preiss, D

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? by Sattar, N, McLaren, J, Kristensen, S, Preiss, D, McMurray, J

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia by Preiss, D, Rosenson, R, Jacobsen, T, Djedjos, C, Dent, R, Bridges, I, Miller, M

Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials by Goldie, C, Taylor, A, Nguyen, P, McCoy, C, Zhao, X, Preiss, D